Theralizumab

Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS) . Theralizumab can be used for the research of rheumatoid arthritis[1][2].

Product Specifications

CAS Number

[906068-56-2]

Product Name Alternative

TGN1412; TAB08

UNSPSC

12352203

Target

CD28

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/theralizumab.html

Purity

99.46

Solubility

H2O

Smiles

[Theralizumab]

Molecular Weight

(145.62 kDa)

References & Citations

[1]Thomas Hünig. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. FEBS J. 2016 Sep;283 (18) :3325-34.|[2]Dmitry Tyrsin, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. Jul-Aug 2016;34 (4 Suppl 98) :45-8.|[3]Weißmüller S, et al. TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One. 2016 Mar 9;11 (3) :e0149093.|[4]Hussain K, et al. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood. 2015 Jan 1;125 (1) :102-10.